Literature DB >> 6409482

Heterophil nature of EVI antibody in Trypanosoma cruzi infection.

E L Khoury, C Diez, P M Cossio, R M Arana.   

Abstract

Previous findings implying the autoreactive capability of circulating complement-fixing (EVI) antibodies in patients with Chagas' disease (American trypanosomiasis), under both in vitro and in vivo conditions have been irreproducible. The presence of the tissue antigens involved in the reactivity with EVI antibodies is exclusively confined to nonhuman substrates, suggesting the heterophil nature of these antibodies which, on the other hand, have also been described in human sera collected in areas free from Chagas' disease. This would preclude any direct pathogenic effect of EVI antibodies when present in the circulation, though they may be useful immunological markers of unsuspected Trypanosoma cruzi infection in endemic areas.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6409482     DOI: 10.1016/0090-1229(83)90078-8

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  10 in total

Review 1.  Chagas' disease and the autoimmunity hypothesis.

Authors:  F Kierszenbaum
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

2.  Antibodies to tubulin in patients with parasitic infections.

Authors:  M K Howard; K Gull; M A Miles
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

3.  A circulating IgG in Chagas' disease which binds to beta-adrenoceptors of myocardium and modulates their activity.

Authors:  E Borda; J Pascual; P Cossio; M De La Vega; R Arana; L Sterin-Borda
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

4.  Autoimmune thyroid diseases in patients with chronic fasciolosis.

Authors:  Mustafa Demirci; S Ercan Tunc; Namik Delibas; M Numan Tamer; Irfan Altuntas; Metin Korkmaz
Journal:  Wien Klin Wochenschr       Date:  2003-03-31       Impact factor: 1.704

Review 5.  Chagas' disease.

Authors:  H B Tanowitz; L V Kirchhoff; D Simon; S A Morris; L M Weiss; M Wittner
Journal:  Clin Microbiol Rev       Date:  1992-10       Impact factor: 26.132

6.  Anti-Trypanosoma cruzi and anti-laminin antibodies in chagasic patients after specific treatment.

Authors:  R T Gazzinelli; L M Galvão; J E Cardoso; J R Cançado; A U Krettli; Z Brener; G Gazzinelli
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

7.  Autoimmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant Trypanosoma cruzi antigen.

Authors:  E Cunha-Neto; M Duranti; A Gruber; B Zingales; I De Messias; N Stolf; G Bellotti; M E Patarroyo; F Pilleggi; J Kalil
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

8.  Longitudinal study of immune response in human Chagas' disease.

Authors:  W Mosca; J Plaja; R Hubsch; R Cedillos
Journal:  J Clin Microbiol       Date:  1985-09       Impact factor: 5.948

9.  Antiheart antibody-dependent cytotoxicity in the sera of mice chronically infected with Trypanosoma cruzi.

Authors:  R P Laguens; P C Meckert; J G Chambó
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

10.  Circulating antibodies to mouse laminin in Chagas disease, American cutaneous leishmaniasis, and normal individuals recognize terminal galactosyl(alpha 1-3)-galactose epitopes.

Authors:  H Towbin; G Rosenfelder; J Wieslander; J L Avila; M Rojas; A Szarfman; K Esser; H Nowack; R Timpl
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.